ClinicalTrials.gg
CompletedNCT02078310Updated Nov 17, 2017

Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

A Phase 1/2 interventional study of ITI-007 and Placebo in Alzheimer's Disease, sponsored by Intra-Cellular Therapies, Inc.. Completed at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 1/2, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2014, 12 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2017.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Alzheimer Disease by Johnson & Johnson — 1 open to participants now, 2 under way, none of them phase 3. Alzheimer Disease · Johnson & Johnson.

Enrollment
39th of 50
35 · median 108
Started
2014
with 5 others
Phase 1/2
Only one
of the 61
Registered
43rd of 61
by date

Among the 61 studies in Alzheimer Disease by Johnson & Johnson, this one is the 39th largest by enrollment of the 50 interventional ones that give a count, is one of 6 that started in 2014, is the only one in phase 1/2, and was the 43rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 61 studies in Alzheimer Disease by Johnson & Johnson is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Alzheimer Disease by Johnson & Johnson, or all of them as a file.
02

Study summary

A Phase 1b/2, Randomized, Double-blind, Placebo-Controlled, Multiple Oral Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients with Dementia

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Dementia,
  • Healthy
  • geriatric
  • volunteers
  • patients
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1

  • Healthy geriatric volunteers
  • score of >= 26 at screening
  • between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening

Part 2

  • Geriatric patients with a clinical diagnosis of dementia
  • MMSE score of \< 26 at screening
  • BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening

Exclusion criteria

Exclusion Criteria:

  • Any illness within 6 months before screening
  • Any history of cancer within last 5 years
  • History of or C infection and elevated , AST or above the level
  • Any subject considered to be an imminent danger to themselves or others
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    ITI-007 Part 1

    Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007

    Drug: ITI-007

  • Placebo comparator
    Placebo Part 1

    Part 1: Healthy geriatric volunteers with placebo given

    Drug: Placebo

  • Experimental
    ITI-007 Part 2

    Part 2: Geriatric patients with dementia with ITI-007 given

    Drug: ITI-007

  • Placebo comparator
    Placebo Part 2

    Part 2: Geriatric patients with dementia with placebo given

    Drug: Placebo

Interventions

  • ITI-007 for Part 1

  • DrugPlacebo

    ITI-007 for Part 1

  • ITI-007 for Part 2

  • DrugPlacebo

    Placebo for Part 2

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Vital signs, 12-lead ECGs, clinical laboratory testing, and adverse events will be assessed.

    Time frame: up to 7 days

Secondary outcomes

  1. Area under the concentration-time curve (AUC)

    Time frame: pre-dose and multiple collection points up to 72 h after the last dose

Other outcomes

  1. Exploratory measures of cognitive function

    Time frame: Baseline and up to 7 days

  2. Exploratory measures of agitation

    Time frame: Baseline and up to 7 days

  3. Exploratory measures of subjective sleep

    Time frame: Baseline and up to 7 days

07

Study locations

1 site
  • Glendale, California, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Aug 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2014
First posted
Mar 5, 2014
Start
Feb 2014
Primary completionActual
Aug 2014
CompletionActual
Nov 2014
Results delay requested
Nov 8, 2017
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02078310
Responsible party
Sponsor
First posted
Mar 5, 2014
Start date
Feb 2014
Primary completion
Aug 2014
Completion
Nov 2014
Last update
Nov 17, 2017

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion